Document:

Exhibit 10.2

  

   

  

  CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.  SUCH EXCLUDED INFORMATION HAS BEEN
    MARKED WITH “[***]”.

   

  

  AMENDMENT NO. 2

   

  This Amendment No. 2 (the “Amendment”) to the Strategic Collaboration Agreement dated July 31st, 2015, as previously amended by
    Amendment No. 1 dated October 18, 2018 (the “Agreement”), is made by and between

   

  

  
    
      	 	
              (1)

            	
              ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Södertälje, Sweden (“AstraZeneca”)

                and

            

    

  

   

  
    
      	 	
              (2)

            	
              IONIS PHARMACEUTICALS, INC., a Delaware corporation, (formally known as Isis Pharmaceuticals, Inc.) having its principal place of business at 2855 Gazelle Court,
                Carlsbad, California 92010 U.S.A. (“Ionis”),

            

    

  

   

  and is made effective as of April 30, 2020 (the “Amendment Effective Date”). 

  

      Recitals 

   

  

  WHEREAS, in accordance with the Agreement, AstraZeneca is Developing from the [***] Program both (i) [***] Products including [***] (each, a “[***] Product”) and (ii) [***] Products (each, a “[***] Product”); and

   

  WHEREAS, the Parties desire to amend and restate certain terms and conditions of the Agreement with respect to [***] Products under the [***] Program.

   

  Agreement

   

  NOW, THEREFORE, in consideration of the mutual covenants contained in this Amendment, and other good and valuable consideration, the receipt and sufficiency of which are hereby
    acknowledged, the Parties, intending to be legally bound, agree as follows:

   

  
    
      
        
          	
                  1.

                	
                  Definitions

                

        

      

    

  

   

  Any capitalized term not separately defined in this Amendment shall have the meaning ascribed to it in the Agreement.

   

  
    
      
        
          	
                  2.

                	
                  Modifications

                

        

      

    

  

   

  
    
      
        
          	 	
                  a.

                	
                  With respect to the [***] Program, AstraZeneca will use Commercially Reasonable Efforts to [***] of the [***] Product known as [***] by [***].

                

        

      

    

  

  
    
      
        
          	 	
                  b.

                	
                  Notwithstanding the provisions of Section 6.4 of the Agreement, upon the earlier of:

                

        

      

    

  

   

  
    
      
        
          	 	
                  (i)

                	
                  [***] by AstraZeneca, its Affiliates or Sublicensees with respect to [***]; and

                

        

      

    

  

   

  
    
      
        
          	 	
                  (ii)

                	
                  [***],

                

        

      

    

  

   

  in accordance with Section 6.5.5 of the Agreement, AstraZeneca will pay to Ionis US$ [***], which shall satisfy AstraZeneca’s obligations under Section

      6.4 of the Agreement for the separate Product Milestone Event Payments of US$[***] for each of [***] and [***] for the Licensed Program that is the [***] Program.

   

  If AstraZeneca, its Affiliates or Sublicensees are unable to achieve [***] by [***] for [***] due to [***] or any action or failure to act by a Third Party
    that is beyond the reasonable control of AstraZeneca, its Affiliates or Sublicensees, provided that AstraZeneca has taken all reasonable actions that would, in the normal course, be expected to have allowed
    such [***] by [***], then AstraZeneca will provide prompt written notice to Ionis containing sufficient detail and supporting documentation of the inability to achieve such [***], such notice to be provided no later than [***] (unless AstraZeneca
    becomes aware after [***] of the inability to achieve such [***], in which case AstraZeneca shall provide such notice as soon as practicable). Within [***] after such notice, the Parties will meet to discuss
    in good faith and agree upon an alternative timeframe applicable to such Product Milestone Event Payment. If the Parties cannot in good faith agree on such an alternative timeframe, then either Party may refer the matter to the Senior Vice President
    for Early CVRM of AstraZeneca and the Executive Vice President and Chief Corporate Development Officer of Ionis (the “Senior Executives”) for resolution. The Senior Executives will meet as
    soon as reasonably possible thereafter and use their good faith efforts to mutually agree upon an alternative timeframe applicable to such Product Milestone Event Payment. Notwithstanding anything herein to the contrary, under no circumstances will the
    Product Milestone Event Payment corresponding to [***] be due later than the due date for achievement of [***] for [***] as determined pursuant to Section 6.5.5 of the Agreement.

  
    
      

  

  
    
      	 	
              c.

            	
              Notwithstanding the provisions of Section 6.4 of the Agreement, in respect of the Licensed Program that is the [***] Program, if the following Product
                Milestone Events are first achieved by a [***] Product, then the corresponding Product Milestone Event Payments in TABLE 1 shall be amended to read as:

            

    

  

   

  
    	
            TABLE 1

          
	
             

            Product Milestone Event

          	
            Product Milestone Event Payment 

            (Applicable only if first achieved by a [***] 

            Product)

          
	
            [***]

          	
            $[***]

          
	
            [***]

          	
            $[***]

          

  

   

  For clarity, in respect of the Licensed Program that is the [***] Program, if the foregoing Product Milestone Events are first achieved by a [***] Product,
    then the corresponding Product Milestone Event Payments shall be as set forth in TABLE 1 of Section 6.4 of the Agreement without amendment.

   

  

  
    
      	 	
              d.

            	
              Notwithstanding that both [***] Products and [***] Products arise from the [***] Program, for purposes of Section 6.7 (Royalty Payments) of the Agreement,
                [***] Products shall be treated as arising from one Licensed Program (and royalties will be due on [***] Products in accordance with Section 2(e) below) and [***] Products shall be treated as arising from another Licensed Program
                (and royalties will be due on [***] Products in accordance with Section 6.7 of the Agreement).

            

       

      

      
        
          

      

    

  

  

  
    
      	 	
              e.

            	
              Solely with respect to such Licensed Program applicable to [***] Products, TABLE 2 in Section 6.7.1 (AstraZeneca Full Royalty) of the
                Agreement shall be amended to read as follows:

            

    

  

   

  
    	
            TABLE 2

          
	
            Royalty Tier

          	
            Annual Worldwide Net Sales of Products from a Licensed Program

            (Applicable onlyto[***]

            Products)

          	
             

            Royalty 

            Rate

          
	
            1

          	
            For the portion of Annual Worldwide Net Sales < $[***]

          	
            [***]%

          
	
            2

          	
            For the portion of Annual Worldwide Net Sales > $[***] but < $[***]

          	
            [***]%

          
	
            3

          	
            For the portion of Annual Worldwide Net Sales > $[***] but < $[***]

          	
            [***]%

          
	
            4

          	
            For the portion of Annual Worldwide Net Sales > $[***]

          	
            [***]%

          

  

   

  
    
      	 	
              f.

            	
              The following shall be added as Section 6.14 to the Agreement: 

            

    

  

   

   “6.14. Commercial Milestones for [***] Products. 

   

  

  As partial consideration for the rights granted to AstraZeneca hereunder, in accordance with Section 6.5.5, AstraZeneca will pay
    to Ionis the milestone payments as set forth in TABLE 3 below when a milestone event listed in TABLE 3 is first achieved by AstraZeneca, its Affiliates or Sublicensees with respect to a [***] Product:

   

  
    	
            TABLE 3

          
	
            Commercial Milestone Event

            If aggregate Net Sales of all [***] 

            Products sold by AstraZeneca, its 

            Affiliates or Sublicensees in a given 

            Calendar Year exceeds the amount 

            stated below for such Calendar Year:

          	
            Commercial Milestone Event Payment 

            then AstraZeneca will pay to Ionis:

          
	
            US$ [***]

          	
            US$ [***]

          
	
            US$ [***]

          	
            US$ [***]

          
	
            US$ [***]

          	
            US$ [***]

          
	
            US$ [***]

          	
            US$ [***]

          
	
            US$ [***]

          	
            US$ [***]

          
	US$ [***]	US$ [***]
	US$ [***]	US$ [***]

     

    

     

  

  
    
      

  

  

  In the event that in a given Calendar Year more than one of the foregoing thresholds set forth in TABLE 3 is exceeded, AstraZeneca will pay to Ionis a separate milestone payment with respect to each such threshold that is exceeded
    in such Calendar Year. Each milestone payment in this Section 6.14 will be payable only upon the first achievement of such milestone event in a given Calendar Year and no
    amounts shall be due for subsequent or repeated achievements of such milestone in subsequent Calendar Years.” 

   

  
    
      	 	
              3.

            	
              Amendment Effective Date

            

    

  

   

  This Amendment shall become effective on the Amendment Effective Date.

   

  
    	 	
            4.

          	
            Entire Agreement

          

  

   

  This Amendment, together with the Agreement, constitutes the entire agreement between the Parties with respect to the subject matter of the Agreement. The Agreement together with this Amendment
    supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement, as amended. Each Party confirms that it is not relying on any representations, warranties, or covenants of the Party except as specifically
    set out in the Agreement as amended. Nothing in this Amendment is intended to limit or exclude any liability or fraud. The Parties hereby agree that subject to the modifications specifically stated in this Amendment, all other terms and conditions of
    the Agreement shall remain in full force and effect.

   

  [Remainder of page intentionally blank. Signatures follow.]

   

  

  
    
      

  

  
    Execution

     

    THIS AMENDMENT IS EXECUTED by the authorized representatives of the Parties as of the date first written above.

  

   

  

  
    
      	
              ASTRAZENECA AB (publ.)

            	
              IONIS PHARMACEUTICALS, INC.

            
	 	
               

            	 	
               

            
	
              Signature:

            	
              /s/ Regina Fritsche-Danielson

              

            	 	
              Signature:

            	
              /s/ Brett Monia

            
	 	
               

            	 	
               

            
	
              Name:

            	
              Regina Fritsche-Danielson

              

            	 	
              Name: 

              

            	
              Brett Monia

            
	 	
               

            	 	
               

            
	
              Title:

               

            	
              SVP and Head of Research and Early
                Development, Cardiovascular, Renal and Metabolic

            	 	
              Title:  

              

            	
              CEOExhibit 10.1
FIRST AMENDMENT
TO
FIFTH AMENDED AND RESTATED CREDIT AGREEMENT
​
Dated as of July 2, 2020
This FIRST AMENDMENT TO FIFTH AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is among CUBIC CORPORATION, a Delaware corporation (the “Company”), CUBIC TRANSPORTATION SYSTEMS, INC., a California corporation (“CTS”), CUBIC DEFENSE APPLICATIONS, INC., a California corporation (“CDA”, and together with CTS and the Company, collectively, the “Borrowers”), the Lenders party hereto and JPMORGAN CHASE BANK, N.A., as administrative agent for the Lenders (the “Administrative Agent”).
PRELIMINARY STATEMENTS:
(1)          The Borrowers, the Lenders and the Administrative Agent have entered into that certain Fifth Amended and Restated Credit Agreement dated as of March 27, 2020 (as amended from time to time, the “Credit Agreement”; capitalized terms used and not otherwise defined herein have the meanings assigned to such terms in the Credit Agreement).
(2)          The Borrowers have requested that the Administrative Agent and the Lenders amend the Credit Agreement as set forth in this Amendment.
(3)          The Administrative Agent and the Lenders party hereto are, on the terms and conditions stated below, willing to grant the request of the Borrowers.
NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
SECTION 1.       Amendment. Effective as of the First Amendment Effective Date (as defined below) and subject to the satisfaction of the conditions precedent set forth in Section 2 of this Amendment, the parties hereto agree that the Credit Agreement is hereby amended to delete the stricken text (indicated textually in the same manner as the following example: stricken text) and to add the double-underlined text (indicated textually in the same manner as the following example: double-underlined text) as set forth in the pages of the Credit Agreement attached as Exhibit B hereto.
SECTION 2.       Conditions to Effectiveness. The amendments in Section 1 of this Amendment shall be effective as of the date (the “First Amendment Effective Date”) the following conditions are satisfied:
(a)         the Administrative Agent’s receipt of counterparts of this Amendment duly executed by the Borrowers, the Administrative Agent and Lenders constituting Required Lenders;
(b)         the Administrative Agent’s receipt of a reaffirmation (the “Reaffirmation”) of the Guarantee by the Guarantors, in the form of Exhibit A, duly executed by each Guarantor party thereto; and
(c)         the Administrative Agent’s (and its affiliates’) receipt of all fees and expenses then due and owing under the Credit Agreement, the other Financing Documents or under any other applicable letter agreement, including, to the extent invoiced, reimbursement or payment of all out-of-
​
​

pocket expenses required to be reimbursed or paid by the Company under the Credit Agreement or other applicable document.
The Administrative Agent shall notify the Borrowers and the Lenders of the First Amendment Effective Date, and such notice shall be conclusive and binding.
SECTION 3.       Representations and Warranties. Each Borrower represents and warrants as follows:
(a)         Authority; Enforceability. Each Borrower has the requisite corporate power and authority to execute, deliver and perform this Amendment, and to perform its obligations under the Credit Agreement as modified hereby and the other Financing Documents to which it is a party.  Each Guarantor has the requisite corporate or limited liability company, as applicable, power and authority to execute, deliver and perform the Reaffirmation, and to perform its obligations under the Reaffirmation and the other Financing Documents to which it is a party. The execution, delivery and performance by each Borrower of this Amendment and by each Guarantor of the Reaffirmation have been duly approved by the board of directors or other governing body, as applicable, of each such Person, and no other corporate proceedings on the part of any Borrower or any Guarantor are necessary to consummate such transactions.  This Amendment has been duly executed and delivered by each Borrower and the Reaffirmation has been duly executed and delivered by each Guarantor.  Each of this Amendment and the Credit Agreement as amended hereby constitutes the legal, valid and binding obligation of each Borrower, enforceable against such Borrower in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency, reorganization or moratorium or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles.  Each of the Guarantee by the Guarantors and the Reaffirmation constitutes the legal, valid and bind obligation of each Guarantor, enforceable against such Guarantor in accordance with its terms except as the enforceability thereof may be limited by bankruptcy, insolvency, reorganization or moratorium or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles.
(b)         Financing Document Representations and Warranties. The representations and warranties contained in each Financing Document are true and correct in all material respects (except that any representation and warranty that is qualified by materiality shall be true and correct in all respects) on and as of the date hereof, before and after giving effect to this Amendment, as though made on and as of such date (unless stated to relate solely to an earlier date, in which case such representations and warranties shall be true and correct in all material respects (except that any representation and warranty that is qualified by materiality shall be true and correct in all respects) as of such earlier date).
(c)         Absence of Default. Except as expressly waived hereby, no event or circumstance has occurred and is continuing, or would result from the effectiveness of this Amendment, that constitutes a Default or an Event of Default.
SECTION 4.       Reference to and Effect on the Financing Documents. (a)  Upon and after the effectiveness of this Amendment, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof’ or words of like import referring to the Credit Agreement, and each reference in the other Financing Documents to “the Credit Agreement”, “thereunder”, “thereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as modified and amended hereby.
(b)         The Credit Agreement and all other Financing Documents are and shall continue to be in full force and effect and are hereby ratified and confirmed in all respects.
​

2

(c)         The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of any Lender or the Administrative Agent under any of the Financing Documents, nor constitute a waiver of any provision of any of the Financing Documents.
(d)         This Amendment is a Financing Document under (and as defined in) the Credit Agreement.
SECTION 5.       Execution in Counterparts. This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which taken together shall constitute but one and the same agreement. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Amendment and/or any document to be signed in connection with this Amendment and the transactions contemplated hereby shall be deemed to include Electronic Signatures, deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be.
SECTION 6.       Governing Law. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK; PROVIDED THAT THE ADMINISTRATIVE AGENT, THE LENDERS AND THE BORROWERS SHALL RETAIN ALL RIGHTS ARISING UNDER FEDERAL LAW.
SECTION 7.       Severability. Whenever possible, each provision of this Amendment shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision of this Amendment shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity without invalidating the remainder of such provision or the remaining provisions of this Amendment.
SECTION 8.       Captions and Headings. The captions or section headings at various places in this Amendment are intended for convenience only and do not constitute and shall not be interpreted as part of this Amendment.
​
[Signature Pages Follow]
​
​

3

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized, as of the date first above written.
​
​
​
	CUBIC CORPORATION, as the Company

	By:
	/s/ Anshooman Aga

	Name:
	Anshooman Aga

	Title:
	Executive Vice President and

	​
	Chief Financial Officer

​
​
	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Vice President, Treasurer

​
​
	CUBIC TRANSPORTATION SYSTEMS, INC., as a Borrower

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Vice President and Treasurer

​
​
	CUBIC DEFENSE APPLICATIONS, INC., as a Borrower

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Treasurer and Assistant Secretary

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	JPMORGAN CHASE BANK, N.A., individually as a

	Lender and as Administrative Agent

	​
	​

	By:
	/s/ Anna C. Araya

	Name:
	Anna C. Araya

	Title:
	Executive Director

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

​
	BANK OF THE WEST, as a Lender

	​
	​

	By:
	/s/ James Wade

	Name:
	James Wade

	Title:
	Director

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	CITIBANK, N.A., as a Lender

	​
	​

	By:
	/s/ Hans Lin

	Name:
	Hans Lin

	Title:
	Director

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	MUFG UNION BANK, N.A., as a Lender

	​
	​

	By:
	/s/ Edmund Ozorio

	Name:
	Edmund Ozorio

	Title:
	Vice President

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	U.S. BANK NATIONAL ASSOCIATION, as a Lender

	​
	​

	By:
	/s/ Glenn Leyrer

	Name:
	Glenn Leyrer

	Title:
	Vice President

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	BANK OF AMERICA, N.A., as a Lender

	​
	​

	By:
	/s/ Aaron Marks

	Name:
	Aaron Marks

	Title:
	Senior Vice President

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	WELLS FARGO BANK, NATIONAL

	ASSOCIATION, as a Lender

	​
	​

	​
	​

	By:
	/s/ Evan Huckaby

	Name:
	Evan Huckaby

	Title:
	Senior Vice President

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	CITY NATIONAL BANK, N.A., as a Lender

	​
	​

	By:
	/s/ Laura Dodd

	Name:
	Laura Dodd

	Title:
	Vice President

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	FIFTH THIRD BANK, as a Lender

	​
	​

	​
	​

	By:
	/s/ Peter Samboul

	Name:
	Peter Samboul

	Title:
	Director

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	RAYMOND JAMES BANK, NATIONAL

	ASSOCIATION, as a Lender

	​
	​

	By:
	/s/ Kathy Bennett

	Name:
	Kathy Bennett

	Title:
	SVP

​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	TRUIST BANK, as a Lender

	​
	​

	By:
	/s/ Anika Kirs

	Name:
	Ankia Kirs

	Title:
	Vice President

​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

	UMPQUA BANK, as a Lender

	​
	​

	By:
	/s/ Kevin Foley

	Name:
	Kevin Foley

	Title:
	SVP

​
​
​

Signature Page to First Amendment to Fifth Amended and Restated Credit Agreement
Cubic Corporation

EXHIBIT A
​
REAFFIRMATION BY THE GUARANTORS
​
Each of the undersigned (a) acknowledges that (i) it has reviewed that certain First Amendment to Fifth Amended and Restated Credit Agreement (the “Amendment”; capitalized terms used and not otherwise defined herein have the meanings assigned to such terms in the Amendment), dated as of July 2, 2020, to that certain Fifth Amended and Restated Credit Agreement dated as of March 27, 2020 (the “Credit Agreement”), among Cubic Corporation, as the Company, the Subsidiary Borrowers party thereto, the Lenders party thereto and JPMorgan Chase Bank, N.A., as the Administrative Agent, (ii) that certain Fifth Amended and Restated Guarantee, dated as of March 27, 2020 (the “Guarantee”), to which it is a party and the other Financing Documents to which it is a party remains in full force and effect, and (iii) under the terms of the Guarantee, it guarantees the Guaranteed Obligations (as defined in the Guarantee) and the other obligations set forth in the Guarantee, and (b) agrees that each Financing Document to which it is a party is hereby reaffirmed, ratified, approved and confirmed in each and every respect, except that, upon the effectiveness of, and on and after the date of, the Amendment, each reference in the Guarantee to the Credit Agreement, “thereunder”, “thereof” or words of like import referring to the Credit Agreement, shall mean and be a reference to the Credit Agreement as amended by the Amendment.
​
​
	CUBIC TRANSPORTATION SYSTEMS, INC., a

	California corporation, as a Guarantor

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Vice President and Treasurer

​
	CUBIC DEFENSE APPLICATIONS, INC., a

	California corporation, as a Guarantor

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Treasurer and Assistant Secretary

​
​

Signature Page to Reaffirmation
Cubic Corporation

	CUBIC ITS, INC., a Texas corporation, as a Guarantor

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Treasurer

​
​
	DELERROK INC., a California corporation, as a

	Guarantor

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Treasurer

​
	GATR TECHNOLOGIES, INC., an Alabama

	corporation, as a Guarantor

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Treasurer

​
​
	ISR SYSTEMS, INC., a Delaware corporation, as a

	Guarantor

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Treasurer

​
​
	NUVOTRONICS, INC., a Delaware corporation, as a

	Guarantor

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Treasurer

​
	PIXIA CORP.., a Delaware corporation, as a

	Guarantor

	​
	​

	By:
	/s/ Rhys Williams

	Name:
	Rhys V. Williams

	Title:
	Treasurer

​
​
​

Signature Page to Reaffirmation
Cubic Corporation

EXHIBIT B
​
[Intentionally Omitted]

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]